Furthermore, recently, a role of activated interleukin 6 (IL-6)/STAT3 signalling has been reported in driving the resistance of BRAF-mutated thyroid cancer cells to vemurafenib, and the blockade of the IL-6 or STAT3 axis has been proposed to increase vemurafenib activity [28]. The gene discussed is IL6; the disease is thyroid gland carcinoma.